CDK9 and plasma cell myeloma: Additionally, the high-risk group demonstrated resistance to several therapeutic agents, including CDK9, cytarabine, docetaxel, epirubicin, mitoxantrone, Obatoclax Mesylate, rapamycin, vincristine, and its synthetic analogues, highlighting the potential of the autophagy prognostic model in predicting treatment resistance in multiple myeloma (MM).